Nanotoxicity: Emerging concerns regarding nanomaterial safety and occupational hard metal (WC-Co) nanoparticle exposure

International Journal of Nanomedicine

Volumn 11, Issue , 2016, Pages 6421-6433

  Armstead, Andrea L ^a,b   Li, Bingyun ^a,b  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Cancer; Engineered nanomaterial; Lung disease; Occupational exposure; Particle; Toxicity

Indexed keywords

CERIUM OXIDE NANOPARTICLE; ENGINEERED NANOMATERIAL; GOLD NANOPARTICLE; LACTATE DEHYDROGENASE; MAGNETITE NANOPARTICLE; NANOMATERIAL; TITANIUM DIOXIDE NANOPARTICLE; UNCLASSIFIED DRUG; ZINC OXIDE NANOPARTICLE; COBALT; NANOPARTICLE; TUNGSTEN CARBIDE; TUNGSTEN DERIVATIVE;

BIOENGINEERING; CANCER RISK; CELL VIABILITY; CONCENTRATION (PARAMETERS); DNA DAMAGE; DUST EXPOSURE; EXPOSURE; HARD METAL LUNG DISEASE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LUNG DISEASE; NANOTOXICOLOGY; NONHUMAN; OCCUPATIONAL EXPOSURE; OCCUPATIONAL SAFETY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PARTICLE SIZE; PROGNOSIS; REVIEW; RISK FACTOR; SURFACE CHARGE; ADVERSE EFFECTS; ANIMAL; CHEMICALLY INDUCED;

ANIMALS; COBALT; HUMANS; LUNG DISEASES; NANOPARTICLES; OCCUPATIONAL EXPOSURE; TUNGSTEN COMPOUNDS;

EID: 85006747567     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S121238     Document Type: Review

References (123)

1. Schrand AM, Dai L, Schlager JJ, Hussain SM. Toxicity testing of nanomaterials. Adv Exp Med Biol. 2012;745:58–75.
2. Hansen SF, Baun A, Michelson ES, Kamper A, Borling P, Stuer-Lauridsen F. Nanomaterials in consumer products: categorization and exposure assessment. In: Nanomaterials: Risks and Benefits. Linkov I, Steevens J, editors. Dordrecht, the Netherlands: Springer; 2009: 359–367.
3. Stamm H, Gibson N, Anklam E. Detection of nanomaterials in food and consumer products: bridging the gap from legislation to enforcement. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2012;29(8):1175–1182.
4. de Silva MN. Nanotechnology and nanomedicine: a new horizon for medical diagnostics and treatment. Arch Soc Esp Oftalmol. 2007;82(6): 331–334.
5. Wang Q, Yan J, Yang J, Li B. Nanomaterials promise better bone repair. Mater Today. 2016;19(8):451–463.
6. Wang X, Ding B, Li B. Biomimetic electrospun nanofibrous structures for tissue engineering. Mater Today (Kidlington). 2013;16(6): 229–241.
7. Zhao J, Castranova V. Toxicology of nanomaterials used in nanomedicine. J Toxicol Environ Health B Crit Rev. 2011;14(8): 593–632.
8. Crommelin DJA, Park K, Florence A. Pharmaceutical nanotechnology: unmet needs in drug delivery. J Control Release. 2010;141(3): 263–264.
9. Luo H, Jiang B, Li B, Li Z, Jiang BH, Chen YC. Kaempferol nanoparticles achieve strong and selective inhibition of ovarian cancer cell viability. Int J Nanomedicine. 2012;7:3951–3959.
10. Armstead AL, Li BY. Nanomedicine as an emerging approach against intracellular pathogens. Int J Nanomedicine. 2011;6:3281–3293.
11. Cassee FR, van Balen EC, Singh C, et al. Exposure, health and ecological effects review of engineered nanoscale cerium and cerium oxide associated with its use as a fuel additive. Crit Rev Toxicol. 2011;41(3): 213–229.
12. Lynam DR, Pfeifer GD, Fort BF, Gelbcke AA. Environmental assessment of MMT fuel additive. Sci Total Environ. 1990;93:107–114.
13. Madl AK, Unice K, Kreider M, Kovochich M, Bebenek IG. Health risk ranking framework for the life cycle of nanomaterial-containing products: comparison of industrial versus consumer application settings. Int J Toxicol. 2013;32(1):65–69.
14. Yan JH, Li BY, Liu XB. Nano-porous sulfur-polyaniline electrodes for lithium-sulfur batteries. Nano Energy. 2015;18:245–252.
15. Yan JH, Liu X, Yao M, Wang X, Wafle TK, Li B. Long-life, high-efficiency lithium-sulfur battery from a nanoassembled cathode. Chem Mater. 2015;27(14):5080–5087.
16. Yan JH, Liu X, Wang X, Li B. Long-life, high-efficiency lithium/sulfur batteries from sulfurized carbon nanotube cathodes. J Mater Chem A. 2015;3(18):10127–10133.
17. Yan JH, Liu XB, Li BY. Nano-assembled Na2FePO4F/carbon nanotube multi-layered cathodes for Na-ion batteries. Electrochem Commun. 2015;56:46–50.
18. Adlakha-Hutcheon G, Khaydarov R, Korenstein R, et al. Nanomaterials, nanotechnology: applications, consumer products, and benefits. In: Linkov I, Steevens J, editors. Nanomaterials: Risks and Benefits. Dordrecht, the Netherlands: Springer; 2009:195–207.
19. Consumer Product Summary: Project on Emerging Nanotechnologies. Available from: http://www.nanotechproject.org/cpi/about/analysis/. Accessed September 14, 2014.
20. Eckelman MJ, Mauter MS, Isaacs JA, Elimelech M. New perspectives on nanomaterial aquatic ecotoxicity: production impacts exceed direct exposure impacts for carbon nanotoubes. Environ Sci Technol. 2012;46(5):2902–2910.
21. Gaiser BK, Fernandes T, Jepson M, Lead JR, Tyler CR, Stone V. Assessing exposure, uptake and toxicity of silver and cerium dioxide nanoparticles from contaminated environments. Environ Health. 2009; 8(Suppl 1):S2.
22. Buzea C, Pacheco II, Robbie K. Nanomaterials and nanoparticles: sources and toxicity. Biointerphases. 2007;2(4):Mr17–Mr71.
23. Keegan GM, Learmonth ID, Case CP. A systematic comparison of the actual, potential, and theoretical health effects of cobalt and chromium exposures from industry and surgical implants. Crit Rev Toxicol. 2008; 38(8):645–674.
24. Sansone V, Pagani D, Melato M. The effects on bone cells of metal ions released from orthopaedic implants. A review. Clin Cases Miner Bone Metab. 2013;10(1):34–40.
25. Simeonova PP, Erdely A. Engineered nanoparticle respiratory exposure and potential risks for cardiovascular toxicity: predictive tests and biomarkers. Inhal Toxicol. 2009;21(Suppl 1):68–73.
26. Cattaneo AG, Gornati R, Sabbioni E, et al. Nanotechnology and human health: risks and benefits. J Appl Toxicol. 2010;30(8):730–744.
27. Stapleton PA, Minarchick VC, McCawley M, Knuckles TL, Nurkiewicz TR. Xenobiotic particle exposure and microvascular end-points: a call to arms. Microcirculation. 2012;19(2):126–142.
28. Nel AE, Mädler L, Velegol D, et al. Understanding biophysico-chemical interactions at the nano-bio interface. Nat Mater. 2009;8(7): 543–557.
29. Song Y, Li X, Wang L, et al. Nanomaterials in humans: identification, characteristics, and potential damage. Toxicol Pathol. 2011;39(5): 841–849.
30. Nurkiewicz TR, Porter DW, Hubbs AF, et al. Pulmonary particulate matter and systemic microvascular dysfunction. Res Rep Health Eff Inst. 2011;164:3–48.
31. Gill HS, Grammatopoulos G, Adshead S, Tsialogiannis E, Tsiridis E. Molecular and immune toxicity of CoCr nanoparticles in MoM hip arthroplasty. Trends Mol Med. 2012;18(3):145–155.
32. Ingham E, Fisher J. Biological reactions to wear debris in total joint replacement. Proc Inst Mech Eng H. 2000;214(H1):21–37.
33. Donaldson K, Schinwald A, Murphy F, et al. The biologically effective dose in inhalation nanotoxicology. Acc Chem Res. 2013;46(3):723–732.
34. Hubbs AF, Mercer RR, Benkovic SA, et al. Nanotoxicology – a pathologist’s perspective. Toxicol Pathol. 2011;39(2):301–324.
35. Lison D, Vietti G, van den Brule S. Paracelsus in nanotoxicology. Part Fibre Toxicol. 2014;11(1):35.
36. Takhar P, Mahant S. In vitro methods for nanotoxicity assessment: advantages and applications. Arch Appl Sci Res. 2011;3(2):389–403.
37. Kroll A, Pillukat MH, Hahn D, Schnekenburger J. Interference of engineered nanoparticles with in vitro toxicity assays. Arch Toxicol. 2012;86(7):1123–1136.
38. Lupu AR, Popescu T. The noncellular reduction of MTT tetrazolium salt by TiO(2) nanoparticles and its implications for cytotoxicity assays. Toxicol In Vitro. 2013;27(5):1445–1450.
39. Guadagnini R, Halamoda Kenzaoui B, Walker L, et al. Toxicity screenings of nanomaterials: challenges due to interference with assay processes and components of classic in vitro tests. Nanotoxicology. 2015;9(Suppl 1):13–24.
40. Fischer HC, Chan WCW. Nanotoxicity: the growing need for in vivo study. Curr Opin Biotechnol. 2007;18(6):565–571.
41. Henderson RF, Driscoll KE, Harkema JR, et al. A comparison of the inflammatory response of the lung to inhaled versus instilled particles in F344 rats. Fundam Appl Toxicol. 1995;24(2):183–197.
42. Yao Z, Stiglich J, Sudarshan T. Nanosized WC-Co holds promise for the future. Metal Powder Report. 1998;53(3):26–33.
43. Yao Z, Stiglich J, Sudarshan T. Nano-grained tungsten carbide-cobalt (WC/Co). Materials Modification Inc.; 1995:1–27. Available from: http://www.matmod.com/publications/armor_1.pdf. Accessed October 21, 2014.
44. Linnainmaa M, Kangas J, Kalliokoski P. Exposure to airborne metals in the manufacture and maintenance of hard metal and stellite blades. Am Ind Hyg Assoc J. 1996;57(2):196–201.
45. Stefaniak AB, Virji MA, Day GA. Characterization of exposures among cemented tungsten carbide workers. Part I: Size-fractionated exposures to airborne cobalt and tungsten particles. J Expo Sci Environ Epidemiol. 2009;19(5):475–491.
46. National Toxicology Program. Cobalt-tungsten carbide: powders and hard metals. Rep Carcinog. 2011;12:115–120.
47. Demedts M, Ceuppens JL. Respiratory diseases from hard metal or cobalt exposure. Solving the enigma. Chest. 1989;95(1):2–3.
48. Kumagai S, Kusaka Y, Goto S. Cobalt exposure level and variability in the hard metal industry of Japan. Am Ind Hyg Assoc J. 1996;57(4): 365–369.
49. Kusaka Y, Goto S. Is there an occupational exposure limit (TLV) present for cobalt? A lesson from hard metal disease in Japan. Adv Prev Occup Respir Dis. 1998;1153:388–392.
50. Kraus T, Schramel P, Schaller KH, Zöbelein P, Weber A, Angerer J. Exposure assessment in the hard metal manufacturing industry with special regard to tungsten and its compounds. Occup Environ Med. 2001;58(10):631–634.
51. Anttila S, Sutinen S, Paananen M, et al. Hard metal lung disease: a clinical, histological, ultrastructural and X-ray microanalytical study. Eur J Respir Dis. 1986;69(2):83–94.
52. Galy P, Bourret P, Tolot P, et al. Pulmonary disorders in the hard metal industry. Rev Inst Hyg Mines (Hasselt). 1974;29(3):130–137.
53. Hartung M. Etiology, pathogenesis and clinical aspects of hard metal fibrosis of the lung. Pneumologie. 1990;44(2):49–54.
54. Lasfargues G, Wild P, Moulin JJ, et al. Lung cancer mortality in a French cohort of hard-metal workers. Am J Ind Med. 1994;26(5): 585–595.
55. Meyer-Bisch C, Pham QT, Mur JM, et al. Respiratory hazards in hard metal workers: a cross sectional study. Br J Ind Med. 1989;46(5): 302–309.
56. Moulin JJ, Wild P, Romazini S, et al. Lung cancer risk in hard-metal workers. Am J Epidemiol. 1998;148(3):241–248.
57. Nemery B, Verbeken EK, Demedts M. Giant cell interstitial pneumonia (hard metal lung disease, cobalt lung). Semin Respir Crit Care Med. 2001;22(4):435–448.
58. Rivolta G, Nocoli E, Ferretti G, Tomasini M. Hard metal lung disorders: analysis of a group of exposed workers. Sci Total Environ. 1994;150(1–3): 161–165.
59. Rochat T, Kaelin RM, Batawi A, Junod AF. Rapidly progressive interstitial lung disease in a hard metal coating worker undergoing hemodialysis. Eur J Respir Dis. 1987;71(1):46–51.
60. Forni A. Bronchoalveolar lavage in the diagnosis of hard metal disease. Sci Total Environ. 1994;150(1–3):69–76.
61. Kinoshita M, Sueyasu Y, Watanabe H, et al. Giant cell interstitial pneumonia in two hard metal workers: the role of bronchoalveolar lavage in diagnosis. Respirology. 1999;4(3):263–266.
62. Dunlop P, Müller NL, Wilson J, Flint J, Churg A. Hard metal lung disease: high resolution CT and histologic correlation of the initial findings and demonstration of interval improvement. J Thorac Imaging. 2005;20(4):301–304.
63. Moriyama H, Kobayashi M, Takada T, et al. Two-dimensional analysis of elements and mononuclear cells in hard metal lung disease. Am J Respir Crit Care Med. 2007;176(1):70–77.
64. Potolicchio I, Mosconi G, Forni A, Nemery B, Seghizzi P, Sorrentino R. Susceptibility to hard metal lung disease is strongly associated with the presence of glutamate 69 in HLA-DP beta chain. Eur J Immunol. 1997;27(10):2741–2743.
65. Tanaka J, Moriyama H, Terada M, et al. An observational study of giant cell interstitial pneumonia and lung fibrosis in hard metal lung disease. BMJ Open. 2014;4(3):e004407.
66. Nureki S, Miyazaki E, Nishio S, Ando M, Kumamoto T. Hard metal lung disease successfully treated with inhaled corticosteroids. Intern Med. 2013;52(17):1957–1961.
67. Enriquez LS, Mohammed TL, Johnson GL, Lefor MJ, Beasley MB. Hard metal pneumoconiosis: a case of giant-cell interstitial pneumonitis in a machinist. Respir Care. 2007;52(2):196–199.
68. Blanc PD. Is giant cell interstitial pneumonitis synonymous with hard metal lung disease? Am J Respir Crit Care Med. 2007;176(8):834; author reply 834–835.
69. Naqvi AH, Hunt A, Burnett BR, Abraham JL. Pathologic spectrum and lung dust burden in giant cell interstitial pneumonia (hard metal disease/cobalt pneumonitis): review of 100 cases. Arch Environ Occup Health. 2008;63(2):51–70.
70. Tabatowski K, Roggli VL, Fulkerson WJ, Langley RL, Benning T, Johnston WW. Giant cell interstitial pneumonia in a hard-metal worker. Cytologic, histologic and analytical electron microscopic investigation. Acta Cytol. 1988;32(2):240–246.
71. Lison D, Lauwerys R, Demedts M, Nemery B. Experimental research into the pathogenesis of cobalt/hard metal lung disease. Eur Respir J. 1996;9(5):1024–1028.
72. Huaux F, Lardot C, Arras M, et al. Lung toxicity of hard metal particles and production of interleukin-1, tumor necrosis factor-alpha, fibronectin, and cystatin-c by lung phagocytes. Toxicol Appl Pharmacol. 1995;132(1):53–62.
73. Antonini JM, Starks K, Roberts JR, Millecchia L, Yang HM, Rao KM. Changes in F-actin organization induced by hard metal particle exposure in rat pulmonary epithelial cells using laser scanning confocal microscopy. In Vitro Mol Toxicol. 2000;13(1):5–16.
74. Bastian S, Busch W, Kühnel D, et al. Toxicity of tungsten carbide and cobalt-doped tungsten carbide nanoparticles in mammalian cells in vitro. Environ Health Perspect. 2009;117(4):530–536.
75. Busch W, Kühnel D, Schirmer K, Scholz S. Tungsten carbide cobalt nanoparticles exert hypoxia-like effects on the gene expression level in human keratinocytes. BMC Genomics. 2010;11:65.
76. Edel J, Sabbioni E, Pietra R, et al. Trace metal lung disease: in vitro interaction of hard metals with human lung and plasma components. Sci Total Environ. 1990;95:107–117.
77. Fenoglio I, Corazzari I, Francia C, Bodoardo S, Fubini B. The oxidation of glutathione by cobalt/tungsten carbide contributes to hard metal-induced oxidative stress. Free Radic Res. 2008;42(8):437–445.
78. Kuhnel D, Scheffler K, Wellner P, et al. Comparative evaluation of particle properties, formation of reactive oxygen species and genotoxic potential of tungsten carbide based nanoparticles in vitro. J Hazard Mater. 2012;227–228:418–426.
79. Lison D, Carbonnelle P, Mollo L, Lauwerys R, Fubini B. Physico-chemical mechanism of the interaction between cobalt metal and carbide particles to generate toxic activated oxygen species. Chem Res Toxicol. 1995;8(4):600–606.
80. Lison D, Lauwerys R. Study of the mechanism responsible for the elective toxicity of tungsten carbide-cobalt powder toward macrophages. Toxicol Lett. 1992;60(2):203–210.
81. Lombaert N, Castrucci E, Decordier I, et al. Hard-metal (WC-Co) particles trigger a signaling cascade involving p38 MAPK, HIF-1alpha, HMOX1, and p53 activation in human PBMC. Arch Toxicol. 2012; 87(2):259–268.
82. Lombaert N, Lison D, Van Hummelen P, Kirsch-Volders M. In vitro expression of hard metal dust (WC-Co) – responsive genes in human peripheral blood mononucleated cells. Toxicol Appl Pharmacol. 2008; 227(2):299–312.
83. Anard D, Kirsch-Volders M, Elhajouji A, Belpaeme K, Lison D. In vitro genotoxic effects of hard metal particles assessed by alkaline single cell gel and elution assays. Carcinogenesis. 1997;18(1):177–184.
84. Ding M, Kisin ER, Zhao J, et al. Size-dependent effects of tungsten carbide-cobalt particles on oxygen radical production and activation of cell signaling pathways in murine epidermal cells. Toxicol Appl Pharmacol. 2009;241(3):260–268.
85. Zhang XD, Zhao J, Bowman L, Shi X, Castranova V, Ding M. Tungsten carbide-cobalt particles activate Nrf2 and its downstream target genes in JB6 cells possibly by ROS generation. J Environ Pathol Toxicol Oncol. 2010;29(1):31–40.
86. Armstead AL, Arena CB, Li B. Exploring the potential role of tungsten carbide cobalt (WC-Co) nanoparticle internalization in observed toxicity toward lung epithelial cells in vitro. Toxicol Appl Pharmacol. 2014;278(1):1–8.
87. Armstead AL, Li B. In vitro inflammatory effects of hard metal (WC-Co) nanoparticle exposure. Int J Nanomedicine. 2016;11:6195–6206.
88. Liu LZ, Ding M, Zheng JZ, et al. Tungsten carbide-cobalt nanoparticles induce reactive oxygen species, AKT, ERK, AP-1, NF-kappaB, VEGF, and angiogenesis. Biol Trace Elem Res. 2015;166(1):57–65.
89. Kitamura H, Yoshimura Y, Tozawa T, Koshi K. Effects of cemented tungsten carbide dust on rat lungs following intratracheal injection of saline suspension. Acta Pathol Jpn. 1980;30(2):241–253.
90. Lasfargues G, Lardot C, Delos M, Lauwerys R, Lison D. The delayed lung responses to single and repeated intratracheal administration of pure cobalt and hard metal powder in the rat. Environ Res. 1995;69(2): 108–121.
91. Lasfargues G, Lison D, Maldague P, Lauwerys R. Comparative study of the acute lung toxicity of pure cobalt powder and cobalt-tungsten carbide mixture in rat. Toxicol Appl Pharmacol. 1992;112(1):41–50.
92. De Boeck M, Hoet P, Lombaert N, Nemery B, Kirsch-Volders M, Lison D. In vivo genotoxicity of hard metal dust: induction of micronuclei in rat type II epithelial lung cells. Carcinogenesis. 2003;24(11):1793–1800.
93. Fedan JS, Cutler D. Hard metal-induced disease: effects of metal cations in vitro on guinea pig isolated airways. Toxicol Appl Pharmacol. 2001;174(3):199–206.
94. Rengasamy A, Kommineni C, Jones JA, Fedan JS. Effects of hard metal on nitric oxide pathways and airway reactivity to methacholine in rat lungs. Toxicol Appl Pharmacol. 1999;157(3):178–191.
95. Adamis Z, Tátrai E, Honma K, Kárpáti J, Ungváry G. A study on lung toxicity of respirable hard metal dusts in rats. Ann Occup Hyg. 1997;41(5):515–526.
96. Armstead AL, Minarchick VC, Porter DW, Nurkiewicz TR, Li B. Acute inflammatory responses of nanoparticles in an intra-tracheal instillation rat model. PLoS One. 2015;10(3):e0118778.
97. Kerfoot EJ, Fredrick WG, Domeier E. Cobalt metal inhalation studies on miniature swine. Am Ind Hyg Assoc J. 1975;36(1):17–25.
98. Lison D, Lauwerys R. Evaluation of the role of reactive oxygen species in the interactive toxicity of carbide-cobalt mixtures on macrophages in culture. Arch Toxicol. 1993;67(5):347–351.
99. Roesems G, Hoet PH, Dinsdale D, Demedts M, Nemery B. In vitro cytotoxicity of various forms of cobalt for rat alveolar macrophages and type II pneumocytes. Toxicol Appl Pharmacol. 2000;162(1):2–9.
100. Lison D, Lauwerys R. Cobalt bioavailability from hard metal particles. Further evidence that cobalt alone is not responsible for the toxicity of hard metal particles. Arch Toxicol. 1994;68(8):528–531.
101. Lombaert N, De Boeck M, Decordier I, Cundari E, Lison D, Kirsch-Volders M. Evaluation of the apoptogenic potential of hard metal dust (WC-Co), tungsten carbide and metallic cobalt. Toxicol Lett. 2004; 154(1–2):23–34.
102. Albanese A, Tang PS, Chan WC. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng. 2012;14:1–16.
103. Geiser M. Morphological aspects of particle uptake by lung phagocytes. Microsc Res Tech. 2002;57(6):512–522.
104. Gauldie J, Jordana M, Cox G. Cytokines and pulmonary fibrosis. Thorax. 1993;48(9):931–935.
105. Park B, Donaldson K, Duffin R, et al. Hazard and risk assessment of a nanoparticulate cerium oxide-based diesel fuel additive – a case study. Inhal Toxicol. 2008;20(6):547–566.
106. Papageorgiou I, Brown C, Schins R, et al. The effect of nano- and micron-sized particles of cobalt-chromium alloy on human fibroblasts in vitro. Biomaterials. 2007;28(19):2946–2958.
107. Papageorgiou I, Shadrick V, Davis S, et al. Macrophages detoxify the genotoxic and cytotoxic effects of surgical cobalt chrome alloy particles but not quartz particles on human cells in vitro. Mutat Res. 2008; 643(1–2):11–19.
108. Papageorgiou I, Yin Z, Ladon D, et al. Genotoxic effects of particles of surgical cobalt chrome alloy on human cells of different age in vitro. Mutat Res. 2007;619(1–2):45–58.
109. Sun L, Li Y, Liu X, et al. Cytotoxicity and mitochondrial damage caused by silica nanoparticles. Toxicol In Vitro. 2011;25(8):1619–1629.
110. Park EJ, Yi J, Chung KH, Ryu DY, Choi J, Park K. Oxidative stress and apoptosis induced by titanium dioxide nanoparticles in cultured BEAS-2B cells. Toxicol Lett. 2008;180(3):222–229.
111. Wilhelmi V, Fischer U, van Berlo D, Schulze-Osthoff K, Schins RP, Albrecht C. Evaluation of apoptosis induced by nanoparticles and fine particles in RAW 264.7 macrophages: facts and artefacts. Toxicol In Vitro. 2012;26(2):323–334.
112. Blum JL, Rosenblum LK, Grunig G, Beasley MB, Xiong JQ, Zelikoff JT. Short-term inhalation of cadmium oxide nanoparticles alters pulmonary dynamics associated with lung injury, inflammation, and repair in a mouse model. Inhal Toxicol. 2014;26(1):48–58.
113. Pauluhn J. Subchronic inhalation toxicity of iron oxide (magnetite, Fe(3) O(4)) in rats: pulmonary toxicity is determined by the particle kinetics typical of poorly soluble particles. J Appl Toxicol. 2012;32(7): 488–504.
114. Minarchick VC, Stapleton PA, Porter DW, et al. Pulmonary cerium dioxide nanoparticle exposure differentially impairs coronary and mesenteric arteriolar reactivity. Cardiovasc Toxicol. 2013;13(4): 323–337.
115. Choi M, Cho M, Han BS, et al. Chitosan nanoparticles show rapid extrapulmonary tissue distribution and excretion with mild pulmonary inflammation to mice. Toxicol Lett. 2010;199(2):144–152.
116. Brown C, Lacharme-Lora L, Mukonoweshuro B, et al. Consequences of exposure to peri-articular injections of micro- and nano-particulate cobalt-chromium alloy. Biomaterials. 2013;34(34):8564–8580.
117. Wang Z, Chen Z, Zuo Q, et al. Reproductive toxicity in adult male rats following intra-articular injection of cobalt-chromium nanoparticles. J Orthop Sci. 2013;18(6):1020–1026.
118. Gaiser BK, Biswas A, Rosenkranz P, et al. Effects of silver and cerium dioxide micro- and nano-sized particles on Daphnia magna. J Environ Monit. 2011;13(5):1227–1235.
119. De Boeck M, Lombaert N, De Backer S, Finsy R, Lison D, Kirsch-Volders M. In vitro genotoxic effects of different combinations of cobalt and metallic carbide particles. Mutagenesis. 2003;18(2):177–186.
120. Kuhnel D, Buscha W, Meißnerb T, et al. Agglomeration of tungsten carbide nanoparticles in exposure medium does not prevent uptake and toxicity toward a rainbow trout gill cell line. Aquat Toxicol. 2009; 93(2–3):91–99.
121. Lison D, Lauwerys R. In vitro cytotoxic effects of cobalt-containing dusts on mouse peritoneal and rat alveolar macrophages. Environ Res. 1990;52(2):187–198.
122. Lison D, Lauwerys R. Biological responses of isolated macrophages to cobalt metal and tungsten carbide-cobalt powders. Pharmacol Toxicol. 1991;69(4):282–285.
123. Lison D, Lauwerys R. The interaction of cobalt metal with different carbides and other mineral particles on mouse peritoneal macrophages. Toxicol In Vitro. 1995;9(3):341–347.